Detalhe da pesquisa
1.
BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme.
Histopathology
; 83(1): 91-103, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36999648
2.
Mechanisms of Cognitive Behavioral Therapy and Light Therapy for Cancer-Related Insomnia: A Randomized Clinical Trial during Chemotherapy for Breast Cancer.
Behav Sleep Med
; 21(3): 227-241, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-35580165
3.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
N Engl J Med
; 379(2): 122-137, 2018 Jul 12.
Artigo
Inglês
| MEDLINE | ID: mdl-29863451
4.
Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
Breast Cancer Res
; 22(1): 91, 2020 08 18.
Artigo
Inglês
| MEDLINE | ID: mdl-32811538
5.
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Br J Cancer
; 122(7): 1119, 2020 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-31949268
6.
The Lancet Breast Cancer Commission.
Lancet
; 2024 Apr 12.
Artigo
Inglês
| MEDLINE | ID: mdl-38636533
7.
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
Breast Cancer Res Treat
; 181(2): 347-359, 2020 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-32274665
8.
Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
Br J Cancer
; 120(3): 279-285, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30655615
9.
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Br J Cancer
; 120(10): 959-967, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30967649
10.
PEG-GCSF-induced aortitis in a patient with breast cancer: distinguishing between infective and immune-mediated aortitis.
Med J Aust
; 220(6): 307-309, 2024 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38379291
11.
Adjuvant ovarian suppression in premenopausal breast cancer.
N Engl J Med
; 372(5): 436-46, 2015 Jan 29.
Artigo
Inglês
| MEDLINE | ID: mdl-25495490
12.
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
N Engl J Med
; 372(10): 923-32, 2015 03 05.
Artigo
Inglês
| MEDLINE | ID: mdl-25738668
13.
Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
Breast Cancer Res
; 24(1): 50, 2022 Jul 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35841108
14.
Correction: The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE".
PLoS Med
; 14(4): e1002302, 2017 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-28430777
15.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
N Engl J Med
; 371(2): 107-18, 2014 Jul 10.
Artigo
Inglês
| MEDLINE | ID: mdl-24881463
16.
The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE".
PLoS Med
; 13(12): e1002204, 2016 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-28027312
17.
Adjuvant ovarian function suppression and cognitive function in women with breast cancer.
Br J Cancer
; 114(9): 956-64, 2016 04 26.
Artigo
Inglês
| MEDLINE | ID: mdl-27092785
18.
Supportive care of women with breast cancer: key concerns and practical solutions.
Med J Aust
; 205(10): 471-475, 2016 Nov 21.
Artigo
Inglês
| MEDLINE | ID: mdl-27852186
19.
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
Lancet Oncol
; 16(7): 848-58, 2015 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-26092816
20.
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Breast Cancer Res Treat
; 154(2): 275-86, 2015 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-26493064